HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bergman, L. Articles by Ragnarsson-Olding, B. Search for Related Content PubMed PubMed Citation Articles by Bergman, L. Articles by Ragnarsson-Olding, B.

Uveal Melanoma Survival in Sweden from 1960 to 1998

¹From the St. Erik’s Eye Hospital and ²Department of General Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.

PURPOSE. To investigate the crude and relative survival rates in patients with uveal melanoma in Sweden during the period from 1960 to 1998.

METHODS. A population-based national survey revealed 2997 cases of uveal melanoma in the Swedish Cancer Registry. The survival rates were calculated by the Hakulinen life-table method, using relative survival as an estimate for deaths due to uveal melanoma. The excess mortality rates were calculated with confidence intervals for the first 15 years after diagnosis. Multivariate regression analysis was undertaken to evaluate the influence of gender, age, and calendar period on relative survival the first 5 years after diagnosis. The underlying causes of deaths in the patients with uveal melanoma, as found in the Cause of Death Registry were also investigated.

RESULTS. Up to December 31, 1998, 2003 patients had died. The 5-year crude survival rate was 60.3% and the relative survival 70.1%. After 10 years, the rates were 42.5% and 59.4%, respectively. Significant excess mortality existed up to 5.5 years after diagnosis. In the multivariate model, younger age (P < 0.001) and later calendar period (P = 0.002), but not gender (P = 0.117), were associated with better relative survival. Deaths due to uveal melanoma were misclassified in the Cause of Death Registry in more than half of the cases.

CONCLUSIONS. This study, covering more than 95% of the uveal melanoma cases in the Swedish population revealed an improvement in relative survival rates for patients with uveal melanoma over time and a significant excess mortality up to 5.5 years after diagnosis.

This article has been cited by other articles:

				W. Maat, L. V. Ly, E. S. Jordanova, D. de Wolff-Rouendaal, N. E. Schalij-Delfos, and M. J. Jager Monosomy of Chromosome 3 and an Inflammatory Phenotype Occur Together in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 505 - 510. [Abstract] [Full Text] [PDF]

				T. Sandinha, M. Farquharson, I. McKay, and F. Roberts Correlation of Heterogeneity for Chromosome 3 Copy Number with Cell Type in Choroidal Melanoma of Mixed-Cell Type Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5177 - 5180. [Abstract] [Full Text] [PDF]

				M. A. Economou, C. All-Ericsson, V. Bykov, L. Girnita, A. Bartolazzi, O. Larsson, and S. Seregard Receptors for the Liver Synthesized Growth Factors IGF-1 and HGF/SF in Uveal Melanoma: Intercorrelation and Prognostic Implications Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4372 - 4375. [Abstract] [Full Text] [PDF]

				M. T. Sandinha, M. A. Farquharson, I. C. McKay, and F. Roberts Monosomy 3 Predicts Death but Not Time until Death in Choroidal Melanoma Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3497 - 3501. [Abstract] [Full Text] [PDF]

				M T Sandinha, M A Farquharson, and F Roberts Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation Br. J. Ophthalmol., December 1, 2004; 88(12): 1527 - 1532. [Abstract] [Full Text] [PDF]

				A D Singh, I G Rennie, T Kivela, S Seregard, and H Grossniklaus The Zimmerman-McLean-Foster hypothesis: 25 years later Br. J. Ophthalmol., July 1, 2004; 88(7): 962 - 967. [Abstract] [Full Text] [PDF]